Tevogen Bio Holdings Inc.
TVGN evidence brief
What we can confirm
- BioSniper Score:
- 3.1 / 10
- Market Cap:
- $47.9M
- Lead Asset:
- tvgn 489 (Phase 1)
What it means
What to watch
Prepared research question
What matters most for TVGN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · TVGN
Tevogen Bio Holdings Inc. (TVGN) is a pre-revenue biotech developing an allogeneic cytotoxic CD8+ T-cell therapy (TVGN 489) for COVID-19 and Long COVID, currently in Phase 1, with limited cash and reliance on debt and grants to fund operations.
Key risk: Cash runway dependency
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$47.9M
Cash Runway
—
Lead Asset
tvgn 489 (Phase 1)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for Tevogen Bio Holdings Inc..
Tevogen Bio Holdings Inc. (TVGN) is a pre-revenue biotech developing an allogeneic cytotoxic CD8+ T-cell therapy (TVGN 489) for COVID-19 and Long COVID, currently in Phase 1, with limited cash and reliance on debt and grants to fund operations.
- Lead pipeline candidate TVGN 489 is an allogeneic cytotoxic CD8+ T-cell therapy targeting multiple antigens on virus-infected cells, currently in Phase 1 for COVID-19 and Long COVID [pipeline].
- As of June 30, 2026, the company had cash of approximately $1.1 million [sec_mda · as of 2026-08-14].
- Net income for the period ended June 30, 2026 was -$5.8M, and shareholders' equity was -$8.9M [sec].
- The company believes its cash, an $11.0 million loan facility, and a remaining $7.0 million grant from KRHP will fund operations for at least 12 months from the date of its unaudited financial statements [sec_mda · as of 2026-08-14].
- Tevogen has devoted substantially all efforts and financial resources since June 2020 to establishing R&D capability and securing intellectual property rights [sec_mda · as of 2026-08-14].
What works
- Tevogen has secured a $7.0 million committed grant from KRHP and a loan agreement providing up to $11.0 million, extending its cash runway to at least 12 months [sec_mda · as of 2026-08-14].
- The company has internally developed patents that it believes have significant value as the basis of its product pipeline [sec_mda · as of 2026-08-14].
- Tevogen's lead candidate TVGN 489 targets multiple, distinct antigens, which may reduce the risk of viral escape compared to single-target therapies [pipeline].
What to weigh
- The company is pre-revenue and has accumulated negative shareholders' equity of -$8.9M as of June 30, 2026 [sec].
- Cash on hand was only $1.1 million as of June 30, 2026, and the company relies on debt and grant funding to continue operations [sec_mda · as of 2026-08-14].
- Tevogen expects to need additional funding to fully implement its business plans, and its future capital requirements depend on uncertain factors such as clinical trial progress and commercialization costs [sec_mda · as of 2026-03-31].
- The company's product candidates may never generate the necessary data to obtain marketing approval or achieve commercial sales [sec_mda · as of 2026-03-31].
From the filings
Quoted directly from source documents.
Cash position as of June 30, 2026
“As of June 30, 2026, we had cash of approximately $1.1 million.”
SEC MD&A · August 14, 2026
Lead pipeline candidate and phase
“Pipeline Candidate: tvgn 489 Indication: COVID-19 and Long COVID Phase: Phase 1”
Company's belief in sufficient cash runway
“we have concluded that we have sufficient cash to fund our operations for at least the next 12 months from the issuance date of our unaudited consolidated financial statements.”
SEC MD&A · August 14, 2026
Risks & what to watch (4)›
Key risks
- Cash runway dependency — Cash of $1.1M as of 2026-06-30, plus loan and grant, may not cover full development costs [sec_mda · as of 2026-08-14].
- Pre-revenue status — No product sales; net loss of $5.8M and negative equity of $8.9M as of 2026-06-30 [sec].
- Clinical trial uncertainty — TVGN 489 is only in Phase 1; may never achieve approval or commercial success [pipeline] [sec_mda · as of 2026-03-31].
- Need for additional funding — Company expects to need more funding to fully implement business plans [sec_mda · as of 2026-03-31].
What to watch
- Progress of TVGN 489 Phase 1 clinical trial for COVID-19 and Long COVID [pipeline].
- Cash burn rate and any new financing or grant announcements [sec_mda · as of 2026-08-14].
- Updates on the $7.0 million KRHP grant and loan agreement drawdowns [sec_mda · as of 2026-08-14].
- Any regulatory milestones or patent prosecution developments [sec_mda · as of 2026-08-14].
Sources: Pipeline · SEC MD&A · Generated October 9, 2026 · How we verify sources →
Run Tevogen Bio Holdings Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Tevogen Bio Holdings Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$6M
Lead: Phase 1
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Financials
Short Interest
as of Apr 20, 2026- % of float
- 8.4%
- Days to cover
- 2.2
- Shares short
- 111,863
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
TVGN short interestGovernance
Frequently asked questions
What is the AI investment thesis for Tevogen Bio Holdings Inc.?
Tevogen Bio Holdings Inc. (TVGN) is a pre-revenue biotech developing an allogeneic cytotoxic CD8+ T-cell therapy (TVGN 489) for COVID-19 and Long COVID, currently in Phase 1, with limited cash and reliance on debt and grants to fund operations.
What is Tevogen Bio Holdings Inc.'s lead drug candidate?
Tevogen Bio Holdings Inc.'s most advanced tracked candidate is tvgn 489 (Phase 1) for COVID-19 and Long COVID.
Who is the CEO of Tevogen Bio Holdings Inc.?
Dr. Ryan H. Saadi M.D., M.P.H. is the chief executive officer of Tevogen Bio Holdings Inc. (TVGN).
Where is Tevogen Bio Holdings Inc. headquartered?
Tevogen Bio Holdings Inc. (TVGN) is headquartered in Warren, NJ, United States.
What therapeutic areas does Tevogen Bio Holdings Inc. focus on?
Tevogen Bio Holdings Inc. develops therapies across Infectious Disease.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.